Safety study of BI115 for advanced small cell lung cancer
Part of Cancer, Lungs & breathing clinical trials.
This early-stage trial tests a new immunotherapy drug called BI115 in people with advanced small cell lung cancer (a fast-growing type of lung cancer). The study will check if the drug is safe and whether it helps slow or shrink the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with advanced small cell lung cancer confirmed by biopsy or cell sample
- You have at least one tumor that can be measured on imaging scans
- You are between 18 and 75 years old
- Your overall health and ability to do daily activities are good (ECOG score 0–1)
- Your blood counts and kidney and liver function are adequate
- You are expected to live at least 12 weeks
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study follows patients with small cell lung cancer who receive radiation therapy combined with other treatments. Researchers will track how well the treatment works and how patients respond over time to help improve future care.
This trial tests a new drug called IBI3009 for people with advanced small cell lung cancer that cannot be removed by surgery. It aims to see how safe the drug is and how well it works against the cancer.
This trial tests a new drug called IBI363 for people with extensive-stage small cell lung cancer whose cancer has continued to grow after immunotherapy and other treatments. It aims to see if IBI363 can help shrink tumors or slow the disease.
This Phase 2 trial tests how well two study drugs (and a combination of them) work in people with extensive-stage small cell lung cancer. It’s mainly for patients whose cancer has come back or who couldn’t tolerate at least some standard treatments, and it aims to see if treatment can shrink tumors and be tolerable.
This Phase 1 study tests how BI 764532 moves into and through tumors in people with small-cell lung cancer or neuroendocrine cancer. It’s likely aimed at understanding the drug’s behavior in your body and tumor, especially if you’ve already tried standard treatments.
This trial tests whether adding IBB0979 (an experimental immunotherapy) to standard chemotherapy (topotecan) works better than topotecan alone for people whose small cell lung cancer has returned or worsened after prior treatment. It aims to find a new option for patients who have limited options.
Hear when a new Small Cell Lung Cancer (SCLC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.